Core Scientific Beats Q3 2026 Estimates as Revenue Rises 187% to $232.9M

Core Scientific (CORZ) beat estimates for the third quarter of 2026 on both revenue and adjusted EPS. Revenue was $232.9 million, up 187% from a year earlier, above the $196.5 million estimate, and adjusted EPS was $0.47 above the -$0.07 estimate.

Shares rose 3.5% in premarket trading as of 7:02 a.m. ET, to $13.21 from a $12.76 close.

Q3 2026 scorecard

By our calculation, revenue was $36.3 million above the estimate and adjusted EPS was $0.54 above it. The QoQ column compares with the previous quarter's revenue of $164.2 million and adjusted EPS of -$3.32. The YoY column compares with $81.1 million and -$0.46 in the same quarter a year earlier.

Track record

• EPS record. Adjusted EPS beat the estimate in 3 of the last 8 reports, including this one.
• Revenue record. Revenue beat the estimate in 2 of the last 8 reports.
• Revenue trend. Revenue over the last 5 reports, oldest first: $81.1 million, $79.8 million, $115.2 million, $164.2 million and $232.9 million.

What to watch

• Next-quarter estimates. Consensus calls for EPS of -$0.05 and revenue of $208.5 million next quarter, based on 3 analysts.
• Revenue growth. Whether revenue keeps growing from a year earlier after this quarter's 187% increase to $232.9 million.
• Estimate record. Whether Core Scientific returns to beating EPS estimates, which it did in 3 of its last 8 reports.
• Related coverage. See our reports on LCI Industries, BKV, Viatris and Peloton Interactive.

Sources: Results are from Core Scientific's Nov. 5, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from Core Scientific's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.